CN110724108B - Esalapril Lin Zhongjian body and preparation method thereof - Google Patents
Esalapril Lin Zhongjian body and preparation method thereof Download PDFInfo
- Publication number
- CN110724108B CN110724108B CN201911126454.2A CN201911126454A CN110724108B CN 110724108 B CN110724108 B CN 110724108B CN 201911126454 A CN201911126454 A CN 201911126454A CN 110724108 B CN110724108 B CN 110724108B
- Authority
- CN
- China
- Prior art keywords
- formula
- scheme
- reaction
- compound
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 102
- -1 phenol compound Chemical class 0.000 claims abstract description 91
- 239000003960 organic solvent Substances 0.000 claims abstract description 72
- 239000002841 Lewis acid Substances 0.000 claims abstract description 37
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 37
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 33
- 238000010520 demethylation reaction Methods 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 161
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 155
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 83
- 239000012074 organic phase Substances 0.000 claims description 82
- 238000006640 acetylation reaction Methods 0.000 claims description 79
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 60
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 48
- 229960001082 trimethoprim Drugs 0.000 claims description 46
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 29
- 230000000397 acetylating effect Effects 0.000 claims description 24
- 238000006460 hydrolysis reaction Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 23
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 21
- 239000012071 phase Substances 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 19
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 17
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 13
- 150000008282 halocarbons Chemical group 0.000 claims description 12
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 11
- 239000012346 acetyl chloride Substances 0.000 claims description 11
- 230000021736 acetylation Effects 0.000 claims description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 3
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 238000010979 pH adjustment Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000012805 post-processing Methods 0.000 claims 4
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 description 141
- 238000004128 high performance liquid chromatography Methods 0.000 description 85
- 238000003756 stirring Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 60
- 239000007787 solid Substances 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- 229940125898 compound 5 Drugs 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 238000010992 reflux Methods 0.000 description 28
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 27
- HWJPWWYTGBZDEG-UHFFFAOYSA-N 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine Chemical compound C=12C=CC(C3CC3)OC2=C(OC)C(OC)=CC=1CC1=CN=C(N)N=C1N HWJPWWYTGBZDEG-UHFFFAOYSA-N 0.000 description 26
- 238000004809 thin layer chromatography Methods 0.000 description 26
- 229940125782 compound 2 Drugs 0.000 description 23
- 239000008346 aqueous phase Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 21
- 238000001816 cooling Methods 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 239000007858 starting material Substances 0.000 description 17
- 239000005457 ice water Substances 0.000 description 16
- CERYEPWGELTBEI-UHFFFAOYSA-N C1(CC1)C1OC2=C(C(=CC(=C2C(C1)=O)CC=1C(=NC(=NC=1)N)N)OC)OC Chemical compound C1(CC1)C1OC2=C(C(=CC(=C2C(C1)=O)CC=1C(=NC(=NC=1)N)N)OC)OC CERYEPWGELTBEI-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229940126214 compound 3 Drugs 0.000 description 14
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 14
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- LEDWOUJPDAFDRJ-UHFFFAOYSA-N 1-[6-[(2,4-diaminopyrimidin-5-yl)methyl]-2-hydroxy-3,4-dimethoxyphenyl]ethanone Chemical compound NC1=NC=C(C(=N1)N)CC1=C(C(=C(C(=C1)OC)OC)O)C(C)=O LEDWOUJPDAFDRJ-UHFFFAOYSA-N 0.000 description 11
- 150000001793 charged compounds Chemical class 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- FLXHQHPYGDVCDP-UHFFFAOYSA-N C1(CC1)C1OC2=C(C(=CC(=C2C(C1)O)CC=1C(=NC(=NC=1)N)N)OC)OC Chemical compound C1(CC1)C1OC2=C(C(=CC(=C2C(C1)O)CC=1C(=NC(=NC=1)N)N)OC)OC FLXHQHPYGDVCDP-UHFFFAOYSA-N 0.000 description 8
- 239000012345 acetylating agent Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229960001925 iclaprim Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- NKIZJHWBAYUHPE-UHFFFAOYSA-N dichloromethane;trichloroborane Chemical compound ClCCl.ClB(Cl)Cl NKIZJHWBAYUHPE-UHFFFAOYSA-N 0.000 description 3
- UXRXKBGRKRYPCP-UHFFFAOYSA-N n-[2-acetamido-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-4-yl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(NC(C)=O)=NC=2)NC(C)=O)=C1 UXRXKBGRKRYPCP-UHFFFAOYSA-N 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- HEMYPJHWBDDJGB-UHFFFAOYSA-N 1-[6-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3,4-trimethoxyphenyl]ethanone Chemical compound NC1=NC=C(C(=N1)N)CC1=C(C(=C(C(=C1)OC)OC)OC)C(C)=O HEMYPJHWBDDJGB-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VVBARWDFWGFRCR-UHFFFAOYSA-N C1(CC1)C1OC2=C(C(=CC(=C2C(=C1)OC)CC=1C(=NC(=NC1)N)N)OC)OC Chemical compound C1(CC1)C1OC2=C(C(=CC(=C2C(=C1)OC)CC=1C(=NC(=NC1)N)N)OC)OC VVBARWDFWGFRCR-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZDWYFWIBTZJGOR-UHFFFAOYSA-N bis(trimethylsilyl)acetylene Chemical group C[Si](C)(C)C#C[Si](C)(C)C ZDWYFWIBTZJGOR-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention discloses an ilarpu Lin Zhongjian body and a preparation method thereof. The invention provides a preparation method of a phenol compound shown in a formula 8, which comprises the following steps of carrying out a selective demethylation reaction of an acetyl compound shown in a formula 2 in the presence of Lewis acid in an organic solvent to obtain the phenol compound shown in the formula 8. The invention also provides an acetyl compound shown in the formula 2, a preparation method and application thereof. The preparation method of the ilaprine intermediate has the advantages of more economical reagent, short route, high yield, low preparation cost, simple post-treatment and suitability for industrial production.
Description
Technical Field
The invention relates to an ilayp Lin Zhongjian body and a preparation method thereof.
Background
The chemical name of the ilaprin (English name: iclaprim) is: 5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine having the structural formula shown below:
icplarim is a dihydrofolate reductase inhibitor developed by Motif Bio corporation, and in 2018, it was filed as a therapeutic drug for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to the us FDA. Iclaprim is currently in phase II clinical trials as a drug for the treatment of Hospital Acquired Bacterial Pneumonia (HABP). In addition, it is currently in preclinical development as a drug for treating staphylococcus aureus lung infection in patients with cystic fibrosis.
In regulatory aspects, iclaprim has been granted qualification for acceptable infectious disease products (QIDP) and rapid channel status by the us FDA. In addition, the FDA awards the status of Iclaprim for the treatment of orphan lung infections of Staphylococcus aureus in cystic fibrosis patients.
At present, in the preparation method of the ilaprin, the main synthesis method is as follows:
the method comprises the following steps: (CN 101115743)
In this route, starting from the compound 1 trimethoprim, the amino group is protected by protection, wherein R represents-C (CH 3 ) 3 or-CH (CH) 3 ) 2 Then Friedel-crafts acetylation, aldol condensation, selective demethylation, ring closure, reduction and elimination, and then hydrolysis reaction are carried out to prepare the ilaprine. The route has a plurality of defects, the reaction route is long, the yield is low by only 4.84 percent (the yield of the step of preparing the compound 14 without the compound 13 is not written in the patent). And each step in the preparation of compound 9 to compound 13 requires column chromatography for purification, which is not suitable for industrial production.
The second method is as follows: (CN 1092194C)
In this route, compound 16 and bis (trimethylsilyl) acetylene are used as starting materials to prepare compound 17, wherein the two starting materials are expensive, and a large amount of expensive catalyst cerium (III) chloride heptahydrate is used in the process of preparing compound 18 by reducing carbonyl with compound 17. And compound 20 needs to be prepared by mitsunobu reaction, which has harsh reaction conditions, extremely low yield and difficult post-treatment. In conclusion, the route has high cost, low yield and complex operation, and is not suitable for industrial production.
Disclosure of Invention
The invention aims to overcome the defects that in the existing synthetic method of the ilaprin, expensive reagents are needed, the cost is high, the post-treatment is complex, the route is long, the yield is low, the method is not suitable for industrial production and the like, and provides the ilaprin intermediate and the preparation method thereof. The preparation method of the ilaprine intermediate has the advantages of more economical reagent, short route, high yield, low preparation cost, simple post-treatment and suitability for industrial production.
The invention solves the technical problems through the following technical proposal.
The invention provides a preparation method of a phenol compound shown in a formula 8, which comprises the following steps of carrying out a selective demethylation reaction of an acetyl compound shown in a formula 2 in the presence of Lewis acid in an organic solvent to obtain the phenol compound shown in the formula 8;
in the present invention, the organic solvent may be a conventional organic solvent in such selective demethylation reactions in the art; halogenated hydrocarbon solvents (e.g., dichloromethane and/or chloroform) are preferred.
The dosage of the organic solvent can be the dosage of the conventional chemical reaction in the selective demethylation reaction in the field so as not to influence the reaction; the volume/mass ratio of the organic solvent to the acetyl compound shown in formula 2 may be 8ml/g-20ml/g (e.g. 10ml/g-15 ml/g).
In the present invention, the lewis acid is preferably boron tribromide and/or boron trichloride. The lewis acid may be used in a form conventional in the art; for example in the form of a solution of the organic solvent (e.g., 1mol/L boron tribromide in methylene chloride).
The molar ratio of the lewis acid to the acetyl compound of formula 2 may be 1:1 to 2:1 (e.g., 1.2:1 to 1.7:1, preferably 1.5:1).
In the present invention, the temperature of the selective demethylation reaction may be a temperature conventional in such selective demethylation reactions in the art, and the present invention is particularly preferably-15℃to 35 ℃ (e.g., -8℃to 30 ℃).
In the present invention, the Lewis acid is preferably added dropwise (e.g., at-8 ℃) to the acetyl compound represented by formula 2 and the organic solvent.
In the present invention, the progress of the selective demethylation reaction can be detected by a conventional monitoring method in the art (for example, TLC, HPLC or NMR), and generally, the end point of the reaction is when the acetyl compound represented by formula 2 disappears or no longer reacts. The reaction time may be 10 to 20 hours.
In the present invention, the conditions for the selective demethylation reaction described above may be carried out in accordance with the conditions in the art for such selective demethylation reaction, except as specifically described above.
In the invention, the preparation method can further comprise post-treatment, wherein the post-treatment comprises the following steps: after the selective demethylation reaction is completed, the reaction system is subjected to extraction (for example, extraction using ice water), pH adjustment to about 6 (for example, using a saturated sodium carbonate aqueous solution), filtration and recrystallization (for example, in isopropanol) to obtain the phenol compound shown in formula 8.
The preparation method of the phenol compound shown in the formula 8 can further comprise a scheme a or a scheme b;
the scheme a comprises the following steps: in an organic solvent, in the presence of Lewis acid, carrying out an acetylation reaction shown below on trimethoprim (a compound shown as a formula 1) and an acetylation reagent to obtain the acetyl compound shown as a formula 2;
the scheme b comprises the following steps: in an organic solvent, in the presence of Lewis acid, performing an acetylation reaction shown in the following on an acetamide compound shown in a formula 1a and an acetylating reagent to obtain the acetyl compound shown in a formula 2;
in the above-mentioned scheme a, the organic solvent may be an organic solvent conventionally used in such an acetylation reaction in the art, and the present invention is preferably a halogenated hydrocarbon solvent such as one or more of chloroform, dichloromethane and dichloroethane, more preferably chloroform.
The dosage of the organic solvent can be the dosage of the conventional chemical reaction in the acetylation reaction in the field, so as not to influence the reaction; the volume to mass ratio of the organic solvent to the trimethoprim may be 5ml/g to 15ml/g (e.g. 8ml/g to 10 ml/g).
In the scheme a, the acetylating reagent can be a conventional acetylating reagent in the acetylating reaction of the type in the field; acetyl chloride and/or acetic anhydride are preferred in the present invention, and acetic anhydride is more preferred.
In the scheme a, the molar ratio of the acetylating reagent to the trimethoprim is preferably 1.5:1 to 4:1 (e.g., 2:1).
In the scheme a, the lewis acid can be a conventional lewis acid in the art of such acetylation reaction; tin tetrachloride is preferred.
In the scheme a, the molar ratio of the Lewis acid to the trimethoprim is preferably 1:1-3:1 (e.g., 2:1-3:1).
In the described scheme a, the temperature of the acetylation reaction may be a temperature conventional in such acetylation reactions in the art, and the present invention is preferably 25℃to 85 ℃ (e.g., 60℃to 65 ℃).
In scheme a, the progress of the acetylation reaction can be monitored by methods conventional in the art (e.g., TLC, HPLC or NMR), typically with the disappearance of the trimethoprim or no longer being reacted as the end point of the reaction. The reaction time may be 1 to 5 hours.
In the above-mentioned scheme a, the respective conditions of the above-mentioned acetylation reaction may be carried out according to the conditions in the art for such acetylation reaction, except for the above-mentioned specific description.
In the scheme a, the method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the acetylation reaction is finished, extracting the reaction system (for example, extracting by using ice water), separating liquid to obtain an organic phase and a water phase, washing the organic phase by using water, extracting the water phase by using an organic solvent (the organic solvent can be chloroform), regulating the pH value of the combined organic phase to 7-8 (for example, saturated sodium carbonate aqueous solution), separating liquid to obtain the organic phase, washing the organic phase by using water, drying the organic phase by using organic phase (for example, anhydrous sodium sulfate), filtering, concentrating (for example, vacuum), recrystallizing (for example, recrystallizing in ethylene glycol monomethyl ether), and obtaining the acetyl compound shown in the formula 2.
In the above-mentioned scheme b, the organic solvent may be an organic solvent conventionally used in such an acetylation reaction in the art, and the present invention is preferably a halogenated hydrocarbon solvent such as one or more of chloroform, dichloromethane and dichloroethane, more preferably chloroform.
The dosage of the organic solvent can be the dosage of the conventional chemical reaction in the acetylation reaction in the field, so as not to influence the reaction; the volume to mass ratio of the organic solvent to the trimethoprim may be 5ml/g to 15ml/g (e.g. 8ml/g to 10 ml/g).
In the scheme b, the acetylating reagent can be a conventional acetylating reagent in the acetylating reaction of the type in the field; acetyl chloride and/or acetic anhydride are preferred in the present invention, and acetic anhydride is more preferred.
In the scheme b, the molar ratio of the acetylating reagent to the trimethoprim is preferably 1.5:1 to 4:1 (e.g., 2:1).
In the scheme b, the Lewis acid can be a conventional Lewis acid in the art of such acetylation reaction; tin tetrachloride is preferred.
In said scheme b, the molar ratio of said Lewis acid to said trimethoprim is preferably 1:1-3:1 (e.g. 2:1-3:1).
In said scheme b, the temperature of said acetylation reaction may be conventional in the art for such acetylation reactions, and the present invention is preferably 25 ℃ -85 ℃ (e.g. 60 ℃ -65 ℃).
In the scheme b, the progress of the acetylation reaction can be detected by a conventional monitoring method in the art (for example, TLC, HPLC or NMR), and generally, the reaction end point is when the acetamide compound represented by formula 1a disappears or no longer reacts. The reaction time may be 1 to 5 hours.
In the above-mentioned scheme b, the respective conditions of the above-mentioned acetylation reaction may be carried out according to the conditions in the art for such acetylation reaction, except for the above-mentioned specific description.
In the scheme b, the method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the acetylation reaction is finished, extracting and inactivating (ice water) the reaction system, separating liquid to obtain an organic phase and a water phase, washing the organic phase with water, extracting the water phase with an organic solvent (for example, the organic solvent can be chloroform), regulating the pH of the combined organic phase to 7-8 (for example, saturated sodium carbonate aqueous solution), separating liquid to obtain the organic phase, washing the organic phase with water, drying (for example, anhydrous sodium sulfate), filtering, concentrating (for example, vacuum), and recrystallizing (for example, recrystallizing in ethylene glycol monomethyl ether) to obtain the acetyl compound shown in the formula 2.
The solution b may further include a solution c, where the solution c may include the following steps: performing acetylation reaction on trimethoprim shown in formula 1 under the action of an acetylating reagent in an organic solvent to obtain an acetamide compound shown in formula 1 a;
in the scheme c, the organic solvent may be a solvent commonly used in such acetylation reaction in the art, toluene is particularly preferred in the present invention.
In the scheme c, the amount of the organic solvent may be an amount of chemical reaction which is conventional in the art, and preferably, the volume/mass ratio of the organic solvent to the trimethoprim shown in the formula 1 is in the range of 5-20ml/g (e.g., 9 ml/g).
In the scheme c, the acetylating agent may be an acetylating agent conventional in the art, and acetic anhydride and/or acetyl chloride are preferred in the present invention.
In the scheme c, the amount of the acetylating agent may be an amount conventional in the art for such acetylations, and preferably the molar ratio of the acetylating agent to the trimethoprim of formula 1 is (2-5): 1 (e.g., 2:1, 4:1, 5:1).
In said scheme c, the temperature of said acetylation reaction may be a temperature commonly used in such acetylation reactions in the art, the present invention being particularly preferred to be 100-110 ℃.
In the scheme c, the progress of the acetylation reaction can be monitored according to a detection method conventional in the art (for example, TLC, HPLC or GC), and generally, the time of the acetylation reaction is preferably 1 to 3 hours (for example, 1.5 hours) with the disappearance of trimethoprim as the end point of the reaction.
In the scheme c, the acetylation reaction may further comprise a post-treatment operation, and the post-treatment method and conditions may be conventional methods and conditions for such acetylation reaction in the art, and in the present invention, the following post-treatment steps are preferably included: crystallization (e.g. cooling the reaction system to room temperature, standing for crystallization), filtration and drying.
In the step of the post-treatment of the acetylation reaction in the scheme c, the crystallization method and conditions may be those conventional in the art, and the present invention is particularly preferably to allow standing crystallization after cooling to room temperature.
The invention provides an acetyl compound shown as a formula 2;
the invention also provides a preparation method of the acetyl compound shown in the formula 2, which comprises the following scheme a or scheme b;
the scheme a comprises the following steps: in an organic solvent, in the presence of Lewis acid, carrying out an acetylation reaction shown below on trimethoprim (a compound shown as a formula 1) and an acetylation reagent to obtain the acetyl compound shown as a formula 2;
the scheme b comprises the following steps: in an organic solvent, in the presence of Lewis acid, performing an acetylation reaction shown in the following on an acetamide compound shown in a formula 1a and an acetylating reagent to obtain the acetyl compound shown in a formula 2;
in the above-mentioned scheme a, the organic solvent may be an organic solvent conventionally used in such an acetylation reaction in the art, and the present invention is preferably a halogenated hydrocarbon solvent such as one or more of chloroform, dichloromethane and dichloroethane, more preferably chloroform.
The dosage of the organic solvent can be the dosage of the conventional chemical reaction in the acetylation reaction in the field, so as not to influence the reaction; the volume to mass ratio of the organic solvent to the trimethoprim may be 5ml/g to 15ml/g (e.g. 8ml/g to 10 ml/g).
In the scheme a, the acetylating reagent can be a conventional acetylating reagent in the acetylating reaction of the type in the field; acetyl chloride and/or acetic anhydride are preferred in the present invention, and acetic anhydride is more preferred.
In the scheme a, the molar ratio of the acetylating reagent to the trimethoprim is preferably 1.5:1 to 4:1 (e.g., 2:1).
In the scheme a, the lewis acid can be a conventional lewis acid in the art of such acetylation reaction; tin tetrachloride is preferred.
In the scheme a, the molar ratio of the Lewis acid to the trimethoprim is preferably 1:1-3:1 (e.g., 2:1-3:1).
In the described scheme a, the temperature of the acetylation reaction may be a temperature conventional in such acetylation reactions in the art, and the present invention is preferably 25℃to 85 ℃ (e.g., 60℃to 65 ℃).
In scheme a, the progress of the acetylation reaction can be monitored by methods conventional in the art (e.g., TLC, HPLC or NMR), typically with the disappearance of the trimethoprim or no longer being reacted as the end point of the reaction. The reaction time may be 1 to 5 hours.
In the above-mentioned scheme a, the respective conditions of the above-mentioned acetylation reaction may be carried out according to the conditions in the art for such acetylation reaction, except for the above-mentioned specific description.
In the scheme a, the method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the acetylation reaction is finished, extracting the reaction system (for example, extracting by using ice water), separating liquid to obtain an organic phase and a water phase, washing the organic phase by using water, extracting the water phase by using an organic solvent (the organic solvent can be chloroform), regulating the pH value of the combined organic phase to 7-8 (for example, saturated sodium carbonate aqueous solution), separating liquid to obtain the organic phase, washing the organic phase by using water, drying the organic phase by using organic phase (for example, anhydrous sodium sulfate), filtering, concentrating (for example, vacuum), recrystallizing (for example, recrystallizing in ethylene glycol monomethyl ether), and obtaining the acetyl compound shown in the formula 2.
In the above-mentioned scheme b, the organic solvent may be an organic solvent conventionally used in such an acetylation reaction in the art, and the present invention is preferably a halogenated hydrocarbon solvent such as one or more of chloroform, dichloromethane and dichloroethane, more preferably chloroform.
The dosage of the organic solvent can be the dosage of the conventional chemical reaction in the acetylation reaction in the field, so as not to influence the reaction; the volume to mass ratio of the organic solvent to the trimethoprim may be 5ml/g to 15ml/g (e.g. 8ml/g to 10 ml/g).
In the scheme b, the acetylating reagent can be a conventional acetylating reagent in the acetylating reaction of the type in the field; acetyl chloride and/or acetic anhydride are preferred in the present invention, and acetic anhydride is more preferred.
In the scheme b, the molar ratio of the acetylating reagent to the trimethoprim is preferably 1.5:1 to 4:1 (e.g., 2:1).
In the scheme b, the Lewis acid can be a conventional Lewis acid in the art of such acetylation reaction; tin tetrachloride is preferred.
In said scheme b, the molar ratio of said Lewis acid to said trimethoprim is preferably 1:1-3:1 (e.g. 2:1-3:1).
In said scheme b, the temperature of said acetylation reaction may be conventional in the art for such acetylation reactions, and the present invention is preferably 25 ℃ -85 ℃ (e.g. 60 ℃ -65 ℃).
In the scheme b, the progress of the acetylation reaction can be detected by a conventional monitoring method in the art (for example, TLC, HPLC or NMR), and generally, the reaction end point is when the acetamide compound represented by formula 1a disappears or no longer reacts. The reaction time may be 1 to 5 hours.
In the above-mentioned scheme b, the respective conditions of the above-mentioned acetylation reaction may be carried out according to the conditions in the art for such acetylation reaction, except for the above-mentioned specific description.
In the scheme b, the method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the acetylation reaction is finished, extracting and inactivating (ice water) the reaction system, separating liquid to obtain an organic phase and a water phase, washing the organic phase with water, extracting the water phase with an organic solvent (for example, the organic solvent can be chloroform), regulating the pH of the combined organic phase to 7-8 (for example, saturated sodium carbonate aqueous solution), separating liquid to obtain the organic phase, washing the organic phase with water, drying (for example, anhydrous sodium sulfate), filtering, concentrating (for example, vacuum), and recrystallizing (for example, recrystallizing in ethylene glycol monomethyl ether) to obtain the acetyl compound shown in the formula 2.
The solution b may further include a solution c, where the solution c may include the following steps: performing acetylation reaction on trimethoprim shown in formula 1 under the action of an acetylating reagent in an organic solvent to obtain an acetamide compound shown in formula 1 a;
in the scheme c, the organic solvent may be a solvent commonly used in such acetylation reaction in the art, toluene is particularly preferred in the present invention.
In the scheme c, the amount of the organic solvent may be an amount of chemical reaction which is conventional in the art, and preferably, the volume/mass ratio of the organic solvent to the trimethoprim shown in the formula 1 is in the range of 5-20ml/g (e.g., 9 ml/g).
In the scheme c, the acetylating agent may be an acetylating agent conventional in the art, and acetic anhydride and/or acetyl chloride are preferred in the present invention.
In the scheme c, the amount of the acetylating agent may be an amount conventional in the art for such acetylations, and preferably the molar ratio of the acetylating agent to the trimethoprim of formula 1 is (2-5): 1 (e.g., 2:1, 4:1, 5:1).
In said scheme c, the temperature of said acetylation reaction may be a temperature commonly used in such acetylation reactions in the art, the present invention being particularly preferred to be 100-110 ℃.
In the scheme c, the progress of the acetylation reaction can be monitored according to a detection method conventional in the art (for example, TLC, HPLC or GC), and generally, the time of the acetylation reaction is preferably 1 to 3 hours (for example, 1.5 hours) with the disappearance of trimethoprim as the end point of the reaction.
In the scheme c, the acetylation reaction may further comprise a post-treatment operation, and the post-treatment method and conditions may be conventional methods and conditions for such acetylation reaction in the art, and in the present invention, the following post-treatment steps are preferably included: crystallization (e.g. cooling the reaction system to room temperature, standing for crystallization), filtration and drying.
In the step of the post-treatment of the acetylation reaction in the scheme c, the crystallization method and conditions may be those conventional in the art, and the present invention is particularly preferably to allow standing crystallization after cooling to room temperature.
The invention also provides a preparation method of the acetophenone compound shown in the formula 3, which comprises the following steps of carrying out the following acetamido hydrolysis reaction on the acetyl compound shown in the formula 2 in the presence of alkali in an organic solvent to obtain the acetophenone compound shown in the formula 3;
in the present invention, the organic solvent may be an organic solvent commonly used in such acetamido hydrolysis reaction in the art, and the present invention is preferably an alcoholic solvent such as one or more of methanol, ethanol, isopropanol, and more preferably methanol.
The organic solvent may be used in an amount that is conventional in the art for such acetamido hydrolysis reactions, so as not to affect the reaction; the volume and mass ratio of the organic solvent to the acetyl compound shown in formula 2 is preferably 5ml/g-15ml/g (e.g. 9ml/g-11 ml/g).
In the present invention, the base may be a conventional base in the art of such acetamido hydrolysis reaction; the present invention is preferably an alkali metal carbonate, such as sodium carbonate and/or potassium carbonate.
The molar ratio of the base to the acetyl compound of formula 2 is preferably 0.1:1 to 1:1 (e.g., 0.1:1 to 0.7:1).
In the present invention, the temperature of the acetamido hydrolysis reaction may be a temperature conventional in such acetamido hydrolysis reaction in the art, and the present invention is preferably 60℃to 82 ℃ (e.g., 65℃to 70 ℃).
In the present invention, the progress of the acetamido hydrolysis reaction can be detected by a conventional monitoring method in the art (such as TLC, HPLC or NMR), and generally, the end point of the reaction is when the acetyl compound shown in formula 2 disappears or no longer reacts. The reaction time may be 0.5 to 2 hours.
In the present invention, the above-mentioned conditions for the acetamido hydrolysis reaction may be carried out according to the conditions in the art for such acetamido hydrolysis reaction, except for the above-mentioned specific description.
In the invention, the preparation method can further comprise post-treatment, wherein the post-treatment comprises the following steps: after the acetamido hydrolysis reaction is finished, crystallizing (for example, under ice bath), filtering, washing with water, and drying the reaction system to obtain the acetophenone compound shown in the formula 3.
In the preparation method of the acetophenone compound shown in the formula 3, the acetyl compound shown in the formula 2 can be prepared by adopting the scheme 1 or the scheme 2 in the preparation method of the acetyl compound shown in the formula 2.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that: the preparation method of the ilaprine intermediate has the advantages of more economical reagent, short route, high yield, low preparation cost, simple post-treatment and suitability for industrial production.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Example 1
Preparation of Compound 1a (N, N' - (5- (3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Compound 1 (100.0 g,344.5 mmol), acetic anhydride (176 g,1710.4 mmol) and 900ml toluene are added into a reaction bottle, heated and refluxed for 1.5h, cooled to room temperature, left to stand for crystallization, filtered and dried to obtain 109.0g of white solid 1a, the yield is 84.5%, the mp.201-203 ℃ and the purity is 98.72% by HPLC detection, 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.41(s,1H),10.09(s,1H),8.36(s,1H),6.48(s,1H),6.34(s,2H),3.84(s,2H),3.71(s,6H),3.61(s,3H),2.16(s,6H)。
example 2
Preparation of Compound 1a (N, N' - (5- (3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Into a reaction flask were charged compound 1 (100.1 g,344.8 mmol), acetyl chloride (98.1 ml,1379.6 mmol) and 900ml toluene, and stirred under reflux with heating for 1.5hCooling to room temperature, standing for crystallization, suction filtering, oven drying to obtain 104.0g white solid 1a with yield of 80.6%, mp.201-203 deg.C, purity 98.70% by HPLC detection, 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.41(s,1H),10.09(s,1H),8.36(s,1H),6.48(s,1H),6.34(s,2H),3.84(s,2H),3.71(s,6H),3.61(s,3H),2.16(s,6H)。
example 3
Preparation of Compound 1a (N, N' - (5- (3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Compound 1 (100.0 g,344.5 mmol), acetic anhydride (70.3 g,688.5 mmol) and 900ml toluene are added into a reaction bottle, heated and refluxed for 1.5h, cooled to room temperature, left to stand for crystallization, filtered and dried to obtain 102.8g of white solid 1a, the yield is 71.7%, the purity is 98.62% by HPLC detection, 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.41(s,1H),10.09(s,1H),8.36(s,1H),6.48(s,1H),6.34(s,2H),3.84(s,2H),3.71(s,6H),3.61(s,3H),2.16(s,6H)。
example 4
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To the reaction flask were added compound 1a (99.9 g,266.8 mmol), acetic anhydride (55.5 g,544.4 mmol) and 1000ml of dichloroethane, and tin tetrachloride (62 ml,537.8 mmol) was slowly added with stirring, followed by heating and refluxing for reaction for 5 hours, cooling to room temperature, pouring the reaction solution into 600ml of ice water, stirring for 20mins, separating the liquid, washing the organic phase with 50ml of water twice, combining the aqueous phase, extracting the aqueous phase with 50ml of dichloroethane for 4 times, combining the organic phase, washing the organic phase with saturated sodium carbonate solution to a pH of about 7, washing the organic phase with 50ml of water for 1 time, drying with anhydrous sodium sulfate, filtering, vacuum concentrating, and recrystallizing with ethylene glycol monomethyl ether to obtain 87.2g of compound 2 in 78.5% yield. mp.204-206 ℃, and the purity of the product is 96.24% by HPLC detection; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.03(s,1H),9.20(s,1H),8.41(s,1H),7.26(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,3H),3.68(s,2H),2.60(s,3H),2.48(s,3H),2.48(s,3H);MS(ESI+):m/z,417([M+H] + )。
Example 5
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a reaction flask, compound 1a (100.0 g,267.1 mmol), acetic anhydride (55.4 g,544.3 mmol) and 1000ml chloroform were added, tin tetrachloride (62 ml,537.8 mmol) was slowly added with stirring, and then the mixture was heated and refluxed for 2 hours, cooled to room temperature, the reaction solution was poured into 600ml ice water and stirred for 20mins, separated, 50ml of water-washed organic phase was twice, the aqueous phase was combined, 50ml of chloroform-extracted aqueous phase was 4 times, the organic phase was combined, saturated sodium carbonate-washed organic phase was brought to pH of about 7, 50ml of water-washed organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and 200ml of ethylene glycol monomethyl ether was recrystallized to obtain 101.3g of compound 2, yield 91.2%. mp.204-206 ℃; purity by HPLC 96.25%; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.03(s,1H),9.20(s,1H),8.41(s,1H),7.26(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,3H),3.68(s,2H),2.60(s,3H),2.48(s,3H),2.48(s,3H);MS(ESI+):m/z,417([M+H] + )。
example 6
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To the reaction flask were added compound 1a (100.1 g,267.4 mmol), acetyl chloride (76.0 ml,1006.9 mmol) and 1000ml chloroform, tin tetrachloride (62 ml,537.8 mmol) was slowly added with stirring, and then the mixture was heated under reflux for 1.5 hours, cooled to room temperature, the reaction mixture was poured into 600ml ice water and stirred for 20mins, the liquid was separated, the organic phase was washed twice with 50ml water, the aqueous phase was combined, the aqueous phase was washed 4 times with 50ml chloroform, the organic phase was combined, the saturated sodium carbonate solution was washed the organic phase to a pH of about 7, the organic phase was washed 1 time with 50ml water, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and recrystallized from 200ml ethylene glycol monomethyl ether to give 99.3g of compound 2 in 89.3% yield. mp.204-206 ℃; purity by HPLC 96.75%; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.03(s,1H),9.20(s,1H),8.41(s,1H),7.26(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,3H),3.68(s,2H),2.60(s,3H),2.48(s,3H),2.48(s,3H);MS(ESI+):m/z,417([M+H] + )。
Example 7
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 250ml reaction flask were added compound 1 (trimethoprim) (10.02 g,34.52 mmol), acetic anhydride (17.06 g,167.11 mmol) and 100ml chloroform, tin tetrachloride (8.00 ml,68.36 mmol) was added with stirring, the reaction was refluxed for 1h, the TLC detected material was substantially disappeared, cooled to room temperature, the reaction solution was poured into 50ml ice water, stirred for 6mins, separated, 5ml of water-washed organic phase was 3 times, combined with water phase, 5ml of chloroform-extracted water phase was 3 times, combined with organic phase, saturated sodium carbonate aqueous solution was adjusted to pH 7-8, separated, 5ml of water-washed organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and recrystallized from ethylene glycol monomethyl ether to give 13.30g of product, yield 92.63%. mp.203-205 ℃; the purity was 96.72% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):10.03(s,1H),9.20(s,1H),8.41,(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,2H),3.68(s,3H),2.60(s,3H),2.48(s,3H),2.19(s,3H);MS(ESI + ):m/z,417([M+H] + ).
Example 8
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Into a 250ml reaction flask were added compound 1 (trimethoprim) (10.00 g,34.45 mmol), acetyl chloride (9.80 ml,138.57 mmol) and 100ml chloroform, tin tetrachloride (8.00 ml,68.36 mmol) was added under stirring, the reaction was refluxed for 1 hour, cooled to room temperature, the reaction solution was poured into 50ml ice water, stirred for 6 minutes, separated, 5ml of water-washed organic phase was 3 times, the aqueous phase was combined, 5ml of chloroform-extracted aqueous phase was 3 times, the organic phase was combined, saturated sodium carbonate aqueous solution was adjusted to pH 7 to 8, separated, 5ml of water-organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and recrystallized from ethylene glycol monomethyl ether to give 12.98g of product The yield thereof was found to be 90.58%. mp.203-205 ℃; the purity was 95.52% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):10.03(s,1H),9.20(s,1H),8.41,(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,2H),3.68(s,3H),2.60(s,3H),2.48(s,3H),2.19(s,3H);MS(ESI + ):m/z,417([M+H] + ).
Example 9
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 250ml reaction flask were added compound 1 (trimethoprim) (10.00 g,34.45 mmol), acetic anhydride (17.06 g,167.11 mmol) and 100ml chloroform, tin tetrachloride (5.30 ml,45.29 mmol) was added with stirring, the reaction was refluxed for 1h, cooled to room temperature, the reaction solution was poured into 50ml ice water, stirred for 6mins, separated, 5ml of water-washed organic phase was 3 times, the aqueous phase was combined, 5ml of chloroform-extracted aqueous phase was 3 times, the organic phase was combined, saturated sodium carbonate aqueous solution was adjusted to pH 7 to 8, the separated solution, 5ml of water-organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and ethylene glycol monomethyl ether was recrystallized to obtain 12.08g of product in 84.30% yield. mp.203-205 ℃; the purity was 95.61% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):10.03(s,1H),9.20(s,1H),8.41,(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,2H),3.68(s,3H),2.60(s,3H),2.48(s,3H),2.19(s,3H);MS(ESI + ):m/z,417([M+H] + ).
Example 10
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Into a 250ml reaction flask were added compound 1 (trimethoprim) (10.00 g,34.45 mmol), acetic anhydride (17.04 g,166.90 mmol) and 100ml chloroform, tin tetrachloride (12.00 ml,68.36 mmol) was added under stirring, the reaction was refluxed for 1 hour, cooled to room temperature, the reaction solution was poured into 50ml ice water, stirred for 6 minutes, separated, 5ml of water-washed organic phase was 3 times, the aqueous phase was combined, 5ml of chloroform-extracted aqueous phase was 3 times, the organic phase was combined, saturated sodium carbonate aqueous solution was adjusted to pH 7-8, separated, 5ml of water-organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and ethylene glycol monomethyl ether was recrystallized to obtain 10.96g of product in yield 76.48%. mp.203-205 ℃; the purity was 95.67% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):10.03(s,1H),9.20(s,1H),8.41,(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,2H),3.68(s,3H),2.60(s,3H),2.48(s,3H),2.19(s,3H);MS(ESI + ):m/z,417([M+H] + ).
Example 11
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 250ml reaction flask were added compound 1 (trimethoprim) (10.00 g,34.45 mmol), acetic anhydride (17.03 g,166.80 mmol) and 100ml dichloromethane, tin tetrachloride (8.00 ml,102.54 mmol) was added with stirring, the reaction was refluxed for 1h, cooled to room temperature, the reaction solution was poured into 50ml ice water, stirred for 6mins, separated, 5ml of water-washed organic phase was 3 times, the aqueous phase was combined, 5ml of chloroform-extracted aqueous phase was 3 times, the organic phase was combined, saturated sodium carbonate aqueous solution was adjusted to pH 7 to 8, the separated solution, 5ml of water-organic phase was 1 time, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and ethylene glycol monomethyl ether was recrystallized to obtain 12.93g product in 90.23% yield. mp.203-205 ℃; the purity was 95.72% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):10.03(s,1H),9.20(s,1H),8.41,(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,2H),3.68(s,3H),2.60(s,3H),2.48(s,3H),2.19(s,3H);MS(ESI + ):m/z,417([M+H] + ).
Example 12
Preparation of Compound 3 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2,3, 4-trimethoxyphenyl) ethanone)
Adding compound 2 (65.00 g,156.25 mmol), potassium carbonate (15.090 g,109.35 mmol) and 600ml methanol into a reaction bottle, stirring and refluxing for 1.5h, stopping heating, cooling to room temperature, placing under ice bath, stirring, slowly stirring for crystallization, suction filtering, washing with water, and drying to obtain 47.00g white solid compound 3, yield of 90.5%, mp.121-123 ℃; the purity was 97.22% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.28(s,1H),6.66(s,1H),6.12,(s,2H),5.70(s,2H),3.82(s,3H),3.75(d,6H,4Hz),3.42(s,2H),2.29(s,3H).
Example 13
Preparation of Compound 3 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2,3, 4-trimethoxyphenyl) ethanone)
Adding compound 2 (65.01 g,156.49 mmol), potassium carbonate (15.091 g,109.36 mmol) and 600ml ethanol into a reaction bottle, heating and refluxing for 1.5h, stopping heating, cooling to room temperature, placing under ice bath, stirring, slowly stirring for crystallization, suction filtering, washing with water, and drying to obtain 45.00g of white solid compound 3, wherein the yield is 86.7%, and the temperature is mp.121-123 ℃; the purity was 97.32% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.28(s,1H),6.66(s,1H),6.12,(s,2H),5.70(s,2H),3.82(s,3H),3.75(d,6H,4Hz),3.42(s,2H),2.29(s,3H).
Example 14
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into a 1L reaction flask were charged compound 3 (30.00 g,90.36 mmol) and 600ml of dichloromethane, cooled to-6℃in an ice-salt bath, 135.5ml of 1mol/L boron tribromide dichloromethane solution was slowly added dropwise, and the reaction was carried out at room temperature for 5 hours after the addition. Cooling to 0 ℃, quenching with 300ml of methanol, stirring for 1h, concentrating the dry solvent in vacuum, and recrystallizing with ethanol to obtain 25.50g of white solid compound 4 with a yield of 88.74%. mp.217 ℃; the purity was 96.10% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 15
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into 500ml reaction flask was charged the compound3 (20.01 g,60.27 mmol) and 200ml chloroform, the ice salt bath was cooled to-6 ℃, 90.5ml of 1mol/L boron tribromide dichloromethane solution was slowly added dropwise, and the reaction was carried out at room temperature for 5 hours after the addition. Cooling to 0 ℃, quenching with methanol, stirring for 1h, vacuum concentrating the dry solvent, and recrystallizing with ethanol to obtain 16.02g of white solid compound 4 with a yield of 83.58%. mp.217 ℃; the purity was 96.08% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 16
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
To a 250ml reaction flask were added compound 3 (10.02 g,30.18 mmol) and 100ml chloroform, cooled to-6℃in an ice-salt bath, 45.3ml of 1mol/L boron trichloride dichloromethane solution was added dropwise, and the mixture was allowed to react at room temperature for 5 hours. Cooling to 0 ℃, quenching with methanol, stirring for 1h, vacuum concentrating the dry solvent, and recrystallizing with ethanol to obtain 7.88g of white solid compound 4 with a yield of 82.10%. mp.217 ℃; the purity was 96.13% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 17
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
To a 500ml reaction flask were added compound 3 (10.11 g,30.45 mmol) and 200ml dichloromethane, cooled to-6℃in an ice-salt bath, 45.7ml of 1mol/L boron trichloride dichloromethane solution was added dropwise, and the mixture was allowed to react at room temperature for 5 hours. Cooling to 0 ℃, quenching with methanol, stirring for 1h, vacuum concentrating the dry solvent, and recrystallizing with ethanol to obtain 7.96g of white solid compound 4 with a yield of 82.20%. mp.217 ℃; the purity was 96.09% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 18
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into a 1L reaction flask were charged compound 3 (30.00 g,90.36 mmol) and 600ml of dichloromethane, cooled to-6℃in an ice-salt bath, and 108.5ml of 1mol/L boron tribromide dichloromethane solution was slowly added dropwise thereto, and the reaction was carried out at room temperature for 5 hours after the addition. Cooling to 0 ℃, quenching with 300ml of methanol, stirring for 1h, concentrating the dry solvent in vacuum, and recrystallizing with ethanol to obtain 21.73g of white solid compound 4 with a yield of 75.62%. mp.217 ℃; the purity was 96.19% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 19
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into a 1L reaction flask were charged compound 3 (30.00 g,90.36 mmol) and 600ml of dichloromethane, cooled to-6℃in an ice-salt bath, 153.5ml of 1mol/L boron tribromide dichloromethane solution was slowly added dropwise, and the reaction was carried out at room temperature for 5 hours after the addition. Cooling to 0 ℃, quenching with 300ml of methanol, stirring for 1h, concentrating the dry solvent in vacuum, and recrystallizing with ethanol to obtain 24.73g of white solid compound 4 with the yield of 86.06%. mp.217 ℃; the purity was 96.10% by HPLC. 1 H-NMR(300MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 20
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into a 250ml reaction flask were charged compound 3 (10.00 g,30.12 mmol) and 100ml chloroform, cooled to-6℃in an ice salt bath, and 1mol/L boron trichloride dichloromethyl was added dropwise51.5ml of an alkane solution was added and the reaction was carried out at room temperature for 5 hours. Cooling to 0 ℃, quenching with methanol, stirring for 1h, concentrating the dry solvent in vacuum, and recrystallizing with ethanol to obtain 7.83g of white solid compound 4 with a yield of 81.75%. mp.217 ℃; the purity was 96.25% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 21
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into a 250ml reaction flask were charged compound 3 (10.00 g,30.12 mmol) and 100ml chloroform, cooled to-6℃in an ice-salt bath, 46.5ml of 1mol/L boron trichloride dichloromethane solution was added dropwise, and the reaction was carried out at room temperature for 5 hours after the addition. Cooling to 0 ℃, quenching with methanol, stirring for 1h, concentrating the dry solvent in vacuum, and recrystallizing with ethanol to obtain 7.58g of white solid compound 4 with the yield of 79.14%. mp.217 ℃; the purity was 96.21% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 22
Preparation of Compound 8 (N, N' - (5- (2-acetyl-3-hydroxy-4, 5-dimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To the reaction flask was added compound 2 (10.005 g,24.050 mmol) and 100ml dichloromethane and the ice salt bath was cooled to-8 ℃. A solution of boron tribromide in methylene chloride (36 ml,36.000 mmol) was slowly added dropwise thereto, and after 1h of reaction, the reaction was allowed to proceed to room temperature for 19h. The reaction solution was poured into 90ml of ice water, the pH of the saturated aqueous sodium carbonate solution was adjusted to about 6, suction filtration was performed, and the cake isopropanol was recrystallized to obtain 8.730g of Compound 8, yield 90.336%. mp 203-205 ℃; the purity was 97.53% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):11.22(s,1H),8.94(s,1H),8.38(s,1H),6.83(s,1H),6.19(s,1H),3.90(s,3H),3.77(s,5H),2.69(s,3H),2.50(s,3H),2.19(s,3H).
Example 23
Preparation of Compound 8 (N, N' - (5- (2-acetyl-3-hydroxy-4, 5-dimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To the reaction flask was added compound 2 (10.000 g,24.038 mmol) and 100ml dichloromethane and the ice salt bath was cooled to-8 ℃. A solution of boron trichloride in methylene chloride (36 ml,36.000 mmol) was slowly added dropwise thereto, and after 1 hour of reaction, the reaction was allowed to proceed at room temperature for 15 hours. The reaction solution was poured into 90ml of ice water, the pH of the saturated aqueous sodium carbonate solution was adjusted to about 6, and the solution was suction-filtered. The filter cake was recrystallized from isopropanol to give 8.700g of compound 8 in 90.023% yield. mp.203-205 ℃; the purity was 97.49% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):11.22(s,1H),8.94(s,1H),8.38(s,1H),6.83(s,1H),6.19(s,1H),3.90(s,3H),3.77(s,5H),2.69(s,3H),2.50(s,3H),2.19(s,3H).
Example 24
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
Into the reaction flask were added compound 8 (5.000 g,12.438 mmol), potassium carbonate (0.172 g,1.244 mmol) and 50ml methanol, and the mixture was heated under reflux for 1.5h, and after cooling to room temperature, the mixture was stirred under ice bath, stirred slowly, stirred for crystallization, suction filtered, washed with water and dried to give 3.901g of compound 4 as a white solid, yield 98.63%, mp.121-123 ℃. The purity was 98.97% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):9.66(s,1H),8.31(s,1H),7.91(s,1H),7.54(s,2H),7.14(s,1H),6.46(s,1H),3.77(s,3H),3.69(s,3H),3.48(s,2H),2.42(s,3H);MS(ESI + ):m/z,319([M+H] + ).
Example 25
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
Into a 100ml reaction flask were charged compound 4 (4.01 g,12.58 mmol), cyclopropylaldehyde (1.07 g,15.29 mmol) and 40ml acetonitrile, and pyrrolidine (1.34 g,18.87 mol) and acetic acid (1.13 g,18.83 mmol) were slowly added dropwise with stirring, stirred at room temperature for 36h, suction filtered, and dried to give 4.57g of an off-white solid compound 5 acetate in a yield of 84.28%, mp168-171 ℃. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),2.78-2.85(m,1H),2.64-2.69(m,1H),1.89(s,3H),1.19-1.25(m,1H)0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,373([M+H] + ).
Acetate of compound 5 (4.57 g,10.63 mmol) was stirred in saturated sodium carbonate solution for 1h, filtered and dried to give 3.93g of an off-white solid in 84.23% yield. mp.152-155 ℃; the purity was 96.13% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.18(s,1H),6.47(s,1H),6.11,(s,2H),5.63(s,2H),3.91-3.99(m,2H),3.77-3.85(m,1H),3.76(s,3H),3.70(s,3H),2.79-2.83(m,1H),2.65-2.69(m,1H),1.20-1.24(m,1H),0.55-0.62(m,2H),0.47-0.48(m,1H),0.40-0.41(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Example 26
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 250ml reaction flask were added compound 4 (11.00 g,34.59 mmol), cyclopropylaldehyde (3.63 g,51.86 mmol) and 110ml acetonitrile, and pyrrolidine (3.68 g,51.83 mmol) and propionic acid (2.557 g,34.56 mmol) were slowly added dropwise with stirring, stirred at room temperature for 36h, filtered, dried to give propionate of compound 5, which was stirred in a saturated sodium carbonate solution for 1h, dried to give 11.11g of compound 5 in 86.81% yield. mp.152-155 ℃; the purity was 96.15% by HPLC. MS (ESI) + ):m/z,371([M+H] + ).
Example 27
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask were added compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.05 g,15.00 mmol) and 40ml acetonitrile, piperidine (1.55 g,18.22 mmol) and acetic acid (1.12 g,18.67 mmol) were slowly added dropwise with stirring, stirring was performed at room temperature for 36h, suction filtration, and drying to give 4.68g of acetate as an off-white solid compound 5 in a yield of 86.52%.
Acetate of compound 5 (4.68 g,10.88 mmol) was stirred in saturated sodium carbonate solution for 1h, filtered and dried to give 4.02g of an off-white solid in 86.38% yield. mp.152-155 ℃; the purity was 96.17% by HPLC.
Example 28
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask was added compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.08 g,15.429 mmol) and 40ml acetonitrile, piperidine (1.57 g,18.44 mmol) and propionic acid (1.38 g,18.67 mmol) were slowly added dropwise with stirring, stirring at room temperature for 36h, suction filtration to give propionate of compound 5, stirring in saturated sodium carbonate solution for 1h, filtering, drying to give 3.98g of off-white solid in 85.52%. mp.152-155 ℃; the purity was 96.11% by HPLC.
Example 29
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
Into a 100ml reaction flask were charged compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.05 g,15.00 mmol) and 40ml acetonitrile, and pyrrolidine (1.35 g,19.01 mol) and acetic acid (1.51 g,25.17 mmol) were slowly added dropwise with stirring, and stirring was carried out at room temperature for 36 hours, suction filtration and drying to give 4.57g of an acetate as an off-white solid compound 5 in a yield of 84.28%.
Acetate of compound 5 (4.54 g,10.56 mmol) was stirred in saturated sodium carbonate solution for 1h, filtered and dried to give 3.91g of an off-white solid in 84.01% yield. mp.152-155 ℃; the purity was 96.11% by HPLC.
Example 30
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask were added compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.05 g,15.00 mmol) and 40ml acetonitrile, and pyrrolidine (1.36 g,19.15 mmol) and acetic acid (0.75 g,12.50 mmol) were slowly added dropwise with stirring, stirred at room temperature for 36h, suction filtered, stirred in saturated sodium carbonate solution for 1h, filtered, dried to give 3.23g of an off-white solid in a total yield of 78.5% (based on compound 4, 12.58 mmol). mp.152-155 ℃; the purity was 96.25% by HPLC.
Example 31
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask was added compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.05 g,15.00 mmol) and 40ml acetonitrile, and pyrrolidine (1.34 g,18.87 mol) and acetic acid (0.38 g,6.33 mmol) were slowly added dropwise with stirring, stirred at room temperature for 36h, suction filtered, dried, stirred in saturated sodium carbonate solution for 1h, filtered, dried, ethanol recrystallized to give 2.82g of off-white solid in 60.59% yield. mp.152-155 ℃; the purity was 96.01% by HPLC.
Example 32
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol)
Into a reaction flask were added compound 5 (4.00 g,10.81 mmol) and 80ml methanol, cooled to 4℃in an ice bath, added sodium borohydride (0.21 g,5.56 mmol), reacted at room temperature for 2.5h, evaporated to dryness, added 40ml water, stirred for 10min, suction filtered, the filter cake was refluxed with methanol for 3h, concentrated in vacuo, and recrystallized from ethanol and water (volume ratio of ethanol to water: 5:1) to give 3.88g of white colorSolid compound 6, yield 96.48%. mp.211-213 ℃; purity by HPLC 99.23%; 1 H-NMR(400MHz,CDCl3).δ(ppm):7.49(s,1H),6.17-6.2(d,3H),5.58-5.64(m,3H),4.93-4.94(d,1H),3.78-3.82(d,1H),3.63(s,3H),3.62(s,3H),3.53-3.57(m,1H),2.24-2.28(m,1H),1.96-2.02(m,1H),1.34-1.37(m,1H),0.49-0.1(d,2H),0.31-0.36(m,2H);MS(ESI+):m/z,373([M+H]+)。
Example 33
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol) to a reaction flask were added Compound 5 (4.00 g,10.81 mmol) and 80ml methanol, cooled to 4℃in an ice bath, sodium borohydride (0.40 g,10.58 mmol) was added, reacted at room temperature for 2.5h, methanol was evaporated to dryness, 40ml water was added, stirred for 10mins, suction filtered, the cake was refluxed with methanol for 3h, ethanol and water were recrystallized to give 3.90g white solid compound 6 in 96.98% yield. mp.211-213 ℃; purity was 99.21% by HPLC; .
Example 34
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol) to a reaction flask were added Compound 5 (4.00 g,10.81 mmol) and 80ml methanol, cooled to 4℃in an ice bath, sodium borohydride (0.29 g,7.67 mmol) was added, reacted at room temperature for 2.5h, methanol was evaporated to dryness, 40ml water was added, stirred for 10mins, suction filtered, the cake was refluxed with methanol for 3h, concentrated in vacuo, ethanol and water were recrystallized to give 3.89g of white solid compound 6 in 96.73% yield. mp.211-213 ℃; the purity was 99.25% by HPLC.
Example 35
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol)
Acetate (4.00 g,9.30 mmol) of compound 5 and 80ml of methanol were added to the reaction flask, the temperature was reduced to 4℃in an ice bath, sodium borohydride (0.53 g,14.02 mmol) was added, the reaction was carried out at room temperature for 2.5 hours, vacuum concentration was carried out, 40ml of water was added, stirring was carried out for 10 minutes, suction filtration was carried out, methanol was added to the filter cake to reflux for 3 hours, vacuum concentration was carried out, and ethanol and water were recrystallized to obtain 3.18g of white solid compound 6 in 91.90% yield. mp.211-213 ℃; the purity was 99.19% by HPLC.
Example 36
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol)
Acetate (4.00 g,9.30 mmol) of compound 5 and 80ml of methanol were added to the reaction flask, the temperature was reduced to 4℃in an ice bath, sodium borohydride (0.70 g,18.52 mmol) was added, the reaction was carried out at room temperature for 2.5 hours, vacuum concentration was carried out, 40ml of water was added, stirring was carried out for 10 minutes, suction filtration was carried out, methanol was added to the filter cake to reflux for 3 hours, vacuum concentration was carried out, and ethanol and water were recrystallized to obtain 3.20g of compound 6 as a white solid, the yield was 92.47%. mp.211-213 ℃; the purity was 99.23% by HPLC.
Example 37
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol)
Acetate (4.00 g,9.30 mmol) of compound 5 and 80ml of methanol were added to the reaction flask, the temperature was reduced to 4℃in an ice bath, sodium borohydride (0.60 g,15.87 mmol) was added, the reaction was carried out at room temperature for 2.5 hours, vacuum concentration was carried out, 40ml of water was added, stirring was carried out for 10 minutes, suction filtration was carried out, methanol was added to the filter cake to reflux for 3 hours, vacuum concentration was carried out, and ethanol and water were recrystallized to obtain 3.17g of white solid compound 6 in 91.61% yield. mp.211-213 ℃; the purity was 99.27% by HPLC.
Example 38
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol) to a reaction flask was added Compound 5 (7.85 g,18.26 mmol) and 150ml ethanol, cooled to 4℃in an ice bath, sodium borohydride (0.69 g,26.46 mmol) was added, reacted at room temperature for 2.5h, concentrated in vacuo, 70ml water was added, stirred for 10mins, filtered with suction, the filter cake was refluxed with methanol for 3h, concentrated in vacuo, ethanol and water recrystallized to give 6.71g white solid compound 6 in 85.02% yield. mp.211-213 ℃; the purity was 99.24% by HPLC.
Example 39
Preparation of Compound 6 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-ol) to a reaction flask were added Compound 5 (4.00 g,10.81 mmol) and 80ml methanol, cooled to 4℃in an ice bath, potassium borohydride (0.76 g,14.09 mmol) was added, reacted at room temperature for 2.5h, concentrated in vacuo, 40ml water was added, stirred for 10mins, filtered with suction, the cake was refluxed with methanol for 3h, concentrated in vacuo, ethanol and water recrystallized to give 3.78g of white solid compound 6 in 93.99% yield. mp.211-213 ℃; the purity was 99.26% by HPLC.
Example 40
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
Compound 6 (2.01 g,5.40mmol, 99.23% purity by hplc) and 20ml tetrahydrofuran are added to a reaction flask, p-toluenesulfonic acid monohydrate (1.54 g,8.10 mmol) is added under stirring, the mixture is heated and refluxed for 1h, no substantial raw material remains by tlc detection, the mixture is cooled to room temperature, a large amount of white solid is precipitated, filtered and dried to obtain 2.54g of p-toluenesulfonate of white solid compound 7, the yield of which is 89.27%; mp.208 ℃; purity by HPLC 99.91%; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):8.06(b,2H),7.45-7.49(m,3H),7.10-7.12(d,2H),6.85(s,1H),6.47(s,1H),6.39-6.42(m,1H),5.75-5.78(m,1H),4.24-4.27(m,1H),3.74(s,3H),-3.72(s,3H),3.57(b,2H),2.28(s,3H),1.12-1.20(m,1H),0.29-0.54(m,4H),MS(ESI+):m/z,355([M+H] + ). P-toluenesulfonate (2.54 g,4.83 mmol) of compound 7 was stirred in a saturated sodium carbonate solution for 1h, filtered off with suction and dried to give 1.71g of compound 7 as a white solid in a total yield of 89.40%. mp.215 ℃; purity by HPLC 99.96%; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):7.07(s,1H),6.45-6.46(d,1H),6.42(s,1H),6.19(s,2H),5.70-5.72(m,1H),5.68(s,2H),4.24-4.26(m,1H),3.70(s,3H),3.71(s,3H),3.52(d,2H),1.11-1.15(m,1H),0.43-0.51(m,2H),0.35-0.39(m,1H),0.30-0.33(m,1H);MS(ESI+):m/z,355([M+H] + )。
example 41
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
Compound 6 (2.00 g,5.38mmol, 99.23% purity by hplc) and 8ml of dimethyl sulfoxide are added into a reaction flask, p-toluenesulfonic acid monohydrate (1.54 g,8.10 mmol) is added under stirring to react for 1h at 80 ℃, no raw material basically remains in tlc detection, cooling to room temperature, adding dichloromethane, washing the dichloromethane phase for 5 times, separating out a large amount of white solid by dichloromethane layer, filtering and drying to obtain 2.53g of p-toluenesulfonic acid salt of compound 7 as white solid, yield 89.36%, mp.208 ℃; HPLC purity 99.92%.
P-toluenesulfonate (2.53 g,4.81 mmol) of compound 7 was stirred in a saturated sodium carbonate solution for 1h, suction filtered and dried to give 1.70g of compound 7 as a white solid in a total yield of 89.32%. mp.215 ℃; the purity was 99.95% by HPLC.
Example 42
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
Compound 6 (2.00 g,5.38mmol, 99.23% purity by hplc) and 20ml methyltetrahydrofuran were added to a reaction flask, p-toluenesulfonic acid monohydrate (1.55 g,8.15 mmol) was added with stirring and reacted for 1h at 80 ℃, tlc detection was performed with substantially no starting material remaining, cooling to room temperature, adding dichloromethane, washing the dichloromethane phase 5 times, separating out a large amount of white solid from the dichloromethane layer, filtering, oven drying to give 2.50g of p-toluenesulfonic acid salt of compound 7 as a white solid, yield 88.30%, mp.208 ℃; HPLC purity 99.94%.
P-toluenesulfonate (2.50 g,4.75 mmol) of compound 7 was stirred in a saturated sodium carbonate solution for 1h, suction filtered and dried to give 1.69g of compound 7 as a white solid in a total yield of 88.80%. mp.215 ℃; the purity was 99.96% by HPLC.
Example 43
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
Compound 6 (2.00 g,5.38mmol, 99.23% purity by hplc) and 20ml acetone were added to a reaction flask, p-toluenesulfonic acid monohydrate (1.53 g,8.04 mmol) was added with stirring, reaction was carried out for 1h at 80 ℃, tlc detection was carried out with substantially no starting material remaining, cooling to room temperature, dichloromethane was added, water washing was carried out for 5 times, a large amount of white solid was separated out by dichloromethane layer, filtration and drying to obtain 2.52g of p-toluenesulfonic acid salt of compound 7 as a white solid, yield 89.01%, mp.208 ℃; HPLC purity 99.95%.
P-toluenesulfonate (2.52 g,4.79 mmol) of compound 7 was stirred in a saturated sodium carbonate solution for 1h, suction filtered and dried to give 1.70g of compound 7 as a white solid in a total yield of 89.32%. mp.215 ℃; the purity was 99.97% by HPLC.
Example 44
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
Compound 6 (2.01 g,5.40mmol, 99.23% hplc purity) and 20ml dimethylformamide are added to a reaction flask, p-toluenesulfonic acid monohydrate (1.53 g,8.04 mmol) is added with stirring and reacted for 1h at 80 ℃, tlc detection shows substantially no starting material remaining, cooling to room temperature, adding dichloromethane, washing dichloromethane phase 5 times, separating out a large amount of white solid from dichloromethane layer, filtering, drying to obtain 2.49g of p-toluenesulfonic acid salt of white solid compound 7, yield 87.51%, mp.208 ℃; HPLC purity 99.96%.
P-toluenesulfonate (2.49 g,4.73 mmol) of compound 7 was stirred in a saturated sodium carbonate solution for 1h, suction filtered and dried to give 1.67g of compound 7 as a white solid in a total yield of 87.30%. mp.215 ℃; the purity was 99.96% by HPLC.
Example 45
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To the reaction flask was added compound 6 (1.70 g,4.57mmol, 99.23% purity by HPLC) and 7ml of dimethyl sulfoxide, trifluoroacetic acid (1.56 g,13.68 mmol) was added with stirring, reacted for 5 hours at 80℃until no substantial material remained by TLC detection, cooled to room temperature, dichloromethane was added, the pH was adjusted to 9 with saturated sodium carbonate solution, separated, the aqueous phase was extracted 3 times with dichloromethane, the organic phases were combined, the organic phases were washed 5 times with water, dried over anhydrous sodium sulfate, concentrated in vacuo, recrystallized from ethanol, and dried to give 1.39g of compound 7 in 85.92% yield. mp.215 ℃; the purity was 98.96% by HPLC.
Example 46
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To the reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% purity by HPLC) and 20ml of methyltetrahydrofuran, trifluoroacetic acid (1.84 g,16.14 mmol) was added with stirring, the reaction was carried out for 5 hours at 80℃until no substantial starting material remained by TLC detection, cooled to room temperature, dichloromethane was added, the pH was adjusted to 9 with saturated sodium carbonate solution, the solution was separated, the aqueous phase was extracted with dichloromethane 3 times, the organic phases were combined, the organic phases were washed 5 times with water, dried over anhydrous sodium sulfate, concentrated in vacuo, recrystallized from ethanol, and dried to give 1.65g of compound 7 in 86.17% yield. mp.215 ℃; the purity was 98.95% by HPLC.
Example 47
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To the reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% purity by HPLC) and 20ml of acetone, trifluoroacetic acid (1.83 g,16.05 mmol) was added with stirring, the reaction was carried out at 80℃for 5 hours, the TLC detection was carried out with substantially no starting material remaining, cooling to room temperature, methylene chloride was added, the pH was adjusted to 9 with saturated sodium carbonate solution, the liquid was separated, the aqueous phase was extracted 3 times with methylene chloride, the organic phases were combined, the organic phases were washed 5 times with water, dried over anhydrous sodium sulfate, concentrated in vacuo, recrystallized from ethanol, and dried to give 1.67g of compound 7, the yield was 87.5%. mp.215 ℃; the purity was 98.97% by HPLC.
Example 48
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To the reaction flask was added compound 6 (2.01 g,5.40mmol, 99.23% purity by HPLC) and 20ml dimethylformamide, trifluoroacetic acid (1.84 g,16.14 mmol) was added with stirring, the reaction was carried out for 5 hours at 80℃until no substantial starting material remained by TLC detection, cooled to room temperature, dichloromethane was added, the pH was adjusted to 9 with saturated sodium carbonate solution, the solution was separated, the aqueous phase was extracted with dichloromethane 3 times, the organic phase was combined, the organic phase was washed with water 5 times, dried over anhydrous sodium sulfate, concentrated in vacuo, recrystallized from ethanol, and dried to give 1.69g of compound 7 in 88.8% yield. mp.215 ℃; the purity was 98.99% by HPLC.
Example 49
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask was added compound 6 (1.69 g,4.54mmol, 99.23% purity by HPLC) and 20ml of tetrahydrofuran, trifluoroacetic acid (1.56 g,13.68 mmol) was added with stirring, the reaction was heated under reflux for 15h, no substantial material remained by TLC detection, dichloromethane was added after tetrahydrofuran was distilled off, the organic phase was adjusted to pH 9 with saturated sodium carbonate solution, separated, the aqueous phase was extracted with dichloromethane 3 times, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo, recrystallized from ethanol, and dried to give 1.43g of compound 7 in 88.44% yield. mp.215 ℃; the purity was 98.89% by HPLC.
Example 50
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To the reaction flask was added a mixed solution of compound 6 (2.21 g,5.94mmol, hplc purity 99.23%), 12ml of tetrahydrofuran and 4ml of dimethyl sulfoxide, methanesulfonic acid (0.856 g,8.91 mmol) was added with stirring, the reaction was heated to reflux for 3h, tlc was allowed to leave substantially no starting material, cooled to room temperature, tetrahydrofuran was concentrated in vacuo, dichloromethane was added, pH was adjusted to 9 with saturated sodium carbonate solution, the layers were separated, the dichloromethane phase was washed 3 times with water, the solvent was distilled off, ethanol was recrystallized, suction filtered, and dried to give 1.52g of compound 7 as a white solid, yield 72.28%. mp.215 ℃; the purity was 98.93% by HPLC.
Example 51
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask, compound 6 (2.00 g,5.38mmol, HPLC purity: 99.23%) and 20ml of tetrahydrofuran were added, concentrated sulfuric acid (0.53 g,5.41 mmol) was added under stirring, the reaction was heated under reflux for 3 hours, cooled to room temperature, suction filtered, and dried to obtain sulfate of compound 7, the filter cake was stirred in a saturated sodium carbonate solution for 1 hour, suction filtered, and dried to obtain 1.72g of compound 7 as a white solid in a total yield of 90.37%. mp.215 ℃; the purity was 98.90% by HPLC.
Example 52
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% purity by HPLC) and 8ml of dimethyl sulfoxide, concentrated sulfuric acid (0.54 g,5.50 mmol) was added with stirring, the reaction was heated to reflux for 3h, TLC was allowed to leave substantially no starting material, cooled to room temperature, dichloromethane was added, the organic phase was adjusted to pH 9 with saturated sodium carbonate solution, separated, the aqueous phase was extracted with dichloromethane 3 times, the organic phase was combined, the organic phase was washed with water 5 times, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, recrystallized from ethanol, suction filtered, and dried to give 1.75g of compound 7 in 91.95% yield. mp.215 ℃; the purity was 98.98% by HPLC.
Example 53
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask, compound 6 (2.00 g,5.38mmol, HPLC purity: 99.23%) and 20ml methyltetrahydrofuran were added, concentrated sulfuric acid (0.54 g,5.51 mmol) was added under stirring, and the mixture was heated under reflux for 3 hours, cooled to room temperature, suction filtered, and dried to give sulfate of compound 7, and the filter cake was stirred in a saturated sodium carbonate solution for 1 hour, suction filtered, and dried to give 1.71g of compound 7 as a white solid in a total yield of 89.85%. mp.215 ℃; the purity was 98.92% by HPLC.
Example 54
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask were added compound 6 (2.00 g,5.38mmol, HPLC purity 99.23%) and 20ml acetone, concentrated sulfuric acid (0.55 g,5.61 mmol) was added under stirring, and the mixture was heated under reflux for 3 hours, cooled to room temperature, suction filtered, and dried to give sulfate of compound 7, and the filter cake was stirred in a saturated sodium carbonate solution for 1 hour, suction filtered, and dried to give 1.72g of compound 7 as a white solid in a total yield of 90.37%. mp.215 ℃; the purity was 98.95% by HPLC.
Example 55
Preparation of Compound 7 (5- [ (2-cyclopropyl-7, 8-dimethoxy-2H-1-benzopyran-5-yl) methyl ] -2, 4-pyrimidine-diamine)
To a reaction flask, compound 6 (1.71 g,4.60mmol, HPLC purity: 99.23%) and 20ml dimethylformamide were added, sulfuric acid (0.48 g,4.90 mmol) was added under stirring, and the mixture was heated under reflux for 3 hours, cooled to room temperature, suction filtered, and dried to give sulfate of compound 7, and the cake was stirred in a saturated sodium carbonate solution for 1 hour, suction filtered, and dried to give 1.46g of compound 7 as a white solid in a total yield of 89.72%. mp.215 ℃; the purity was 98.97% by HPLC.
Comparative example 1
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 50ml reaction flask were added compound 1a (2.576 g,6.888 mmol), acetic anhydride (3.510 g,34.438 mmol) and 20ml chloroform, and aluminum trichloride (2.230 g,16.724 mmol) was slowly added with stirring and reacted under reflux for 10 hours without the formation of the target substance.
Comparative example 2
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Into a reaction flask, compound 1a (100.0 g,267.1 mmol), acetic anhydride (55.4 g,544.3 mmol) and 1000ml of dichloromethane were added, tin tetrachloride (62 ml,537.8 mmol) was slowly added under stirring, and then the mixture was heated and refluxed for 3 hours, cooled to room temperature, the reaction solution was poured into 600ml of ice water, stirred for 20mins, separated, the organic phase was washed twice with 50ml of water, the aqueous phase was combined, the aqueous phase was washed with 50ml of dichloromethane 4 times, the organic phase was combined, the saturated sodium carbonate solution was washed with the organic phase until the pH was about 7, the organic phase was washed with 1 time with 50ml of water, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo Shrinking, 200ml ethylene glycol monomethyl ether recrystallization, gives 60.2g of compound 2, yield 54.2%. mp.204-206 ℃; purity by HPLC 96.05%; 1 H-NMR(400MHz,CDCl 3 ).δ(ppm):10.03(s,1H),9.20(s,1H),8.41(s,1H),7.26(s,1H),6.34(s,1H),3.95(s,3H),3.84(s,3H),3.76(s,3H),3.68(s,2H),2.60(s,3H),2.48(s,3H),2.48(s,3H);MS(ESI+):m/z,417([M+H] + )。
comparative example 3
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 50ml reaction flask were added compound 1 trimethoprim (2.000 g,6.889 mmol), acetic anhydride (3.516 g,34.440 mmol) and 20ml chloroform, and aluminum trichloride (2.235 g,16.762 mmol) was slowly added with stirring, and the reaction was heated under reflux for 10 hours without the formation of the target substance.
Comparative example 4
Preparation of Compound 2 (N, N' - (5- (2-acetyl-3, 4, 5-trimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 50ml reaction flask were added compound 1 trimethoprim (2.000 g,6.889 mmol), acetic anhydride (3.502 g,34.303 mmol) and 20ml chloroform, and iron trichloride (2.234 g,13.773 mmol) was slowly added with stirring, and the mixture was heated to reflux for 12 hours and cooled to room temperature, whereby no target substance was formed.
Comparative example 5
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
To a 100ml reaction flask were added compound 3 (3.000 g,9.036 mmol) and 60ml dichloromethane, and aluminum trichloride (2.410 g,18.077 mmol) was slowly added with stirring, and the reaction was heated under reflux for 10 hours, whereby no target compound was formed.
Comparative example 6
Preparation of Compound 4 (1- (6- ((2, 4-diaminopyrimidin-5-yl) methyl) -2-hydroxy-3, 4-dimethoxyphenyl) ethanone)
To a 100ml reaction flask was added compound 3 (4.000 g,12.048 mmol), 20ml acetic acid and 48% hydrobromic acid 10ml, and the reaction was heated under reflux for 1h, and the TLC detection of the starting material was essentially complete but no target compound was formed.
Comparative example 7
Preparation of Compound 8 (N, N' - (5- (2-acetyl-3-hydroxy-4, 5-dimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
To a 100ml reaction flask were added compound 2 (4.000 g, 9.015 mmol), 60ml dichloromethane and aluminum trichloride (2.412 g,18.089 mmol), and the reaction was heated under reflux for 10 hours without the formation of the objective compound.
Comparative example 8
Preparation of Compound 8 (N, N' - (5- (2-acetyl-3-hydroxy-4, 5-dimethoxybenzyl) pyrimidine-2, 4-diyl) diacetamide)
Into a 100ml reaction flask were charged compound 2 (4.000 g, 9.616 mmol), 20ml acetic acid and 48% hydrobromic acid 10ml, and the reaction was heated under reflux for 2 hours, and the TLC detection of the starting material was essentially complete but no target compound was formed.
Comparative example 9
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask were added compound 4 (4.000 g,12.579 mmol), cyclopropylaldehyde (1.071 g,15.300 mmol) and 40ml acetonitrile, and pyrrolidine (1.38 g,19.437 mmol) was slowly added dropwise, stirred at room temperature for 36h, concentrated in vacuo, and isolated and purified by thin layer column chromatography to give 0.156g of compound 5 in 3.9% yield. mp.152-155 ℃. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31,(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),1.89(s,3H),1.19-1.25(m,1H),0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Comparative example 10
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
Into a 100ml reaction flask were charged compound 4 (4.0111 g, 12.313 mmol), cyclopropylaldehyde (1.072 g,15.314 mmol) and 40ml acetonitrile, piperidine (1.607 g,18.875 mol) was slowly added dropwise, stirred at room temperature for 48 hours, concentrated in vacuo to dryness, and separated and purified by thin layer column chromatography to give 0.105g of compoundProduct 5, yield 2.25%. mp.152-155 ℃. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31,(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),1.89(s,3H),1.19-1.25(m,1H),0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Comparative example 11
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask were added compound 4 (4.000 g,12.579 mmol), cyclopropylaldehyde (1.082 g,15.457 mmol) and 40ml acetonitrile, and pyrrolidine (1.377 g,18.841 mol) was slowly added dropwise, stirred at room temperature for 50h, concentrated in vacuo, and isolated and purified by thin layer column chromatography to give 0.175g of compound 5 in 3.76% yield. mp.152-155 ℃. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31,(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),1.89(s,3H),1.19-1.25(m,1H),0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Comparative example 12
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
A100 ml reaction flask was charged with compound 4 (4.000 g,12.579 mmol), cyclopropylaldehyde (1.070 g, 15.284 mmol), 40ml of methanol and potassium hydroxide (1.060 g,18.687 mol), and the reaction was heated under reflux for 10 hours, without the formation of the objective compound 5.
Comparative example 13
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
A100 ml reaction flask was charged with compound 4 (4.001 g, 12.284 mmol), cyclopropylaldehyde (1.072 g,15.314 mmol), 40ml of tetrahydrofuran and potassium tert-butoxide (2.090 g,18.629 mol), and the reaction was heated under reflux for 8 hours, without the formation of the objective compound 5.
Comparative example 14
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
Into a 100ml reaction flask were charged compound 4 (4.018 g,12.635 mmol), cyclopropylaldehyde (1.082 g,15.457 mmol) and 40ml isopropyl alcohol, and pyrrolidine (1.347g, 18.972 mol) was slowly added dropwise, stirred at room temperature for 36 hours, dried solvent was concentrated in vacuo, and isolated and purified by thin layer column chromatography to give 0.598g compound 5 in 15.0% yield. mp.152-155 ℃. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31,(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),1.89(s,3H),1.19-1.25(m,1H),0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Comparative example 15
Preparation of Compound 5 (2-cyclopropyl-5- ((2, 4-diaminopyrimidin-5-yl) methyl) -7, 8-dimethoxy chroman-4-one)
To a 100ml reaction flask was added compound 4 (4.00 g,12.58 mmol), cyclopropylaldehyde (1.05 g,15.00 mmol) and 40ml acetonitrile, and pyrrolidine (1.35 g,19.01 mol) was slowly added dropwise with stirring, stirred at room temperature for 36h, suction filtered, dried, ethanol recrystallized to give 2.15g of off-white solid with a yield of 46.20%. mp.152-155 ℃; the purity was 96.63% by HPLC. 1 H-NMR(400MHz,CDCl 3 )δ(ppm):7.13(s,1H),6.49(s,1H),6.31,(s,2H),5.92(s,2H),3.89-4.00(m,2H),3.78-3.86(m,4H),3.71(s,3H),1.89(s,3H),1.19-1.25(m,1H),0.53-0.63(m,2H),0.45-0.51(m,1H),0.37-0.43(m,1H);MS(ESI + ):m/z,371([M+H] + ).
Comparative example 16
Preparation of Compound 7 (5- ((2-cyclopropyl-7, 8-dimethoxy-2H-benzopyran-5-yl) methyl) pyrimidine-2, 4-diamine)
To the reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% pure by HPLC), 20ml of methanol and p-toluenesulfonic acid monohydrate (1.53 g,8.04 mmol), and after stirring at room temperature for 0.5h, the starting material was substantially disappeared by TLC but no target compound was formed. Methanol was concentrated in vacuo, pH was adjusted to 9 by addition of 20ml of saturated aqueous sodium carbonate, extraction was performed three times with 10ml of dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo to give dichloromethane, and the crude product was recrystallized from isopropanol and water (isopropanol: water=2:1) in solvent to give 1.75g of an alcoholic hydroxymethylated compound of compound 6 (5- ((2-cyclopropyl-4, 7, 8-trimethoxybenzopyran-5-yl) methyl) pyrimidine-2, 4-diamine) in a yield of 84.3%.
mp.237-240℃; 1 H-NMR(600MHz,DMSO).δ(ppm):7.44(s,1H),6.30(s,1H),6.15(s,2H),5.74(s,2H),4.41-4.42(t,1H),3.70(s,6H),3.57-3.59(d,1H),3.49-3.52(d,1H),3.39-3.42(m,4H),2.39-2.42(d,2H),1.65-1.70(m,1H),1.20-1.24(m,1H),0.61-0.69(m,2H),0.52-0.56(m,1H),0.38-0.42(m,1H);MS(ESI + ):m/z,387([M+H] + )。
Comparative example 17
Preparation of Compound 7 (5- ((2-cyclopropyl-7, 8-dimethoxy-2H-benzopyran-5-yl) methyl) pyrimidine-2, 4-diamine)
To the reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% HPLC purity), 20ml toluene and 3.07g,26.9mmol of trifluoroacetic acid, and after stirring under heating and refluxing for 2 hours, the TLC examined the substantial disappearance of the starting material but no target compound.
Comparative example 18
Preparation of Compound 7 (5- ((2-cyclopropyl-7, 8-dimethoxy-2H-benzopyran-5-yl) methyl) pyrimidine-2, 4-diamine)
To the reaction flask, compound 6 (2.00 g,5.38mmol, HPLC purity: 99.23%) and 20ml of dilute sulfuric acid (2 mol/L) were added, and after stirring at room temperature for 2 hours, the TLC detected substantial disappearance of starting material but no formation of the objective product.
Comparative example 19
Preparation of Compound 7 (5- ((2-cyclopropyl-7, 8-dimethoxy-2H-benzopyran-5-yl) methyl) pyrimidine-2, 4-diamine)
To the reaction flask was added compound 6 (2.00 g,5.38mmol, 99.23% pure by HPLC), 20ml of methanol and p-toluenesulfonic acid monohydrate (1.54 g,8.10 mmol), and after stirring under reflux for 0.5h, the starting material was substantially disappeared by TLC but no target compound was formed. Methanol was concentrated in vacuo, pH was adjusted to 9 by addition of 20ml of saturated aqueous sodium carbonate, extraction was performed three times with 10ml of dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo to give dichloromethane, and the crude product was recrystallized from isopropanol and water (isopropanol: water=2:1) in solvent to give 1.80g of the alcoholic hydroxymethylated compound of compound 6 (5- ((2-cyclopropyl-4, 7, 8-trimethoxybenzopyran-5-yl) methyl) pyrimidine-2, 4-diamine) in 86.7% yield.
mp.237-240℃; 1 H-NMR(600MHz,DMSO).δ(ppm):7.44(s,1H),6.30(s,1H),6.15(s,2H),5.74(s,2H),4.41-4.42(t,1H),3.70(s,6H),3.57-3.59(d,1H),3.49-3.52(d,1H),3.39-3.42(m,4H),2.39-2.42(d,2H),1.65-1.70(m,1H),1.20-1.24(m,1H),0.61-0.69(m,2H),0.52-0.56(m,1H),0.38-0.42(m,1H);MS(ESI+):m/z,387([M+H]+)。
Comparative example 20
Preparation of Compound 7 (5- ((2-cyclopropyl-7, 8-dimethoxy-2H-benzopyran-5-yl) methyl) pyrimidine-2, 4-diamine)
To the reaction flask, compound 6 (2.01 g,5.40mmol, HPLC purity: 99.23%) and 20ml of dilute sulfuric acid (2 mol/L) were added, and after stirring under heating and refluxing for 1 hour, the TLC detected substantial disappearance of starting material but no formation of the objective product.
Comparative example 21
To the reaction flask was added compound 1b (2.000 g, 4.640 mmol), 10ml DCM and acetic anhydride (1.513 g, 14.812 mmol) under nitrogen, followed by a slow dropwise addition of (2.7 ml,23.072 mmol) tin chloride under ice-bath. Stirring was carried out at room temperature for 18 hours, without formation of compound 2 a.
On the basis that the compound 2a cannot be obtained, the target compound cannot be prepared by continuously referring to the reaction route of the invention.
Claims (11)
1. The preparation method of the phenol compound shown in the formula 8 is characterized by comprising the following steps of carrying out the following selective demethylation reaction of the acetyl compound shown in the formula 2 in the presence of Lewis acid in an organic solvent to obtain the phenol compound shown in the formula 8;
wherein the Lewis acid is boron tribromide and/or boron trichloride.
2. The method for producing a phenol compound represented by the formula 8 according to claim 1,
the organic solvent is a halogenated hydrocarbon solvent;
and/or the volume-mass ratio of the organic solvent to the acetyl compound shown in the formula 2 is 8ml/g-20ml/g;
and/or the molar ratio of the Lewis acid to the acetyl compound shown as the formula 2 is 1:1-2:1;
and/or, the lewis acid is in the form of a solution of the organic solvent;
and/or, the temperature of the selective demethylation reaction is-15 ℃ to 35 ℃;
and/or dropwise adding the Lewis acid into the acetyl compound shown in the formula 2 and the organic solvent;
and/or, the preparation method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the selective demethylation reaction is finished, the reaction system is subjected to extraction, pH adjustment to about 6, filtration and recrystallization, and the phenol compound shown in the formula 8 is obtained.
3. The method for producing a phenol compound represented by the formula 8 according to claim 2,
when the organic solvent is a halogenated hydrocarbon solvent, the halogenated hydrocarbon solvent is dichloromethane and/or chloroform;
And/or the volume-mass ratio of the organic solvent to the acetyl compound shown in the formula 2 is 10ml/g-15ml/g;
and/or the molar ratio of the Lewis acid to the acetyl compound shown as the formula 2 is 1.2:1-1.7:1;
and/or, the temperature of the selective demethylation reaction is-8 ℃ to 30 ℃.
4. The method for producing a phenol compound represented by formula 8 according to claim 1, which further comprises scheme a or scheme b;
the scheme a comprises the following steps: in an organic solvent, in the presence of Lewis acid, carrying out an acetylation reaction shown below on trimethoprim and an acetylation reagent to obtain the acetyl compound shown in the formula 2;
wherein the Lewis acid is tin tetrachloride;
the scheme b comprises the following steps: in an organic solvent, in the presence of Lewis acid, performing an acetylation reaction shown in the following on an acetamide compound shown in a formula 1a and an acetylating reagent to obtain the acetyl compound shown in a formula 2;
wherein the Lewis acid is tin tetrachloride.
5. The method for producing a phenol compound represented by the formula 8 according to claim 4,
In the scheme a, the organic solvent is a halogenated hydrocarbon solvent;
and/or in the scheme a, the volume-mass ratio of the organic solvent to the trimethoprim is 5ml/g-15ml/g;
and/or, in the scheme a, the acetylating reagent is acetyl chloride and/or acetic anhydride;
and/or, in the scheme a, the molar ratio of the acetylation reagent to the trimethoprim is 3:1-6:1;
and/or, in the scheme a, the molar ratio of the Lewis acid to the trimethoprim is 1:1-3:1;
and/or, in the scheme a, the temperature of the acetylation reaction is 25-85 ℃;
and/or, in the scheme a, the method further comprises post-processing, wherein the post-processing comprises the following steps: after the acetylation reaction is finished, extracting and removing the reaction system to obtain an organic phase and a water phase, washing the organic phase with water, extracting the water phase with an organic solvent, regulating the pH value of the combined organic phase to 7-8, separating the water phase to obtain the organic phase, washing the organic phase with water, drying the organic phase, filtering, concentrating, and recrystallizing to obtain the acetyl compound shown in the formula 2;
and/or, in the scheme b, the organic solvent is a halogenated hydrocarbon solvent;
And/or in the scheme b, the volume-mass ratio of the organic solvent to the trimethoprim is 5ml/g-15ml/g;
and/or, in the scheme b, the acetylating reagent is acetyl chloride and/or acetic anhydride;
and/or, in the scheme b, the molar ratio of the acetylation reagent to the trimethoprim is 3:1-6:1;
and/or in the scheme b, the molar ratio of the Lewis acid to the trimethoprim is 1:1-3:1;
and/or, in the scheme b, the temperature of the acetylation reaction is 25-85 ℃;
and/or, in the scheme b, the method further comprises post-processing, wherein the post-processing comprises the following steps: after the acetylation reaction is finished, extracting and removing the reaction system to obtain an organic phase and a water phase, washing the organic phase with water, extracting the water phase with an organic solvent, regulating the pH value of the combined organic phase to 7-8, separating the water phase to obtain the organic phase, washing the organic phase with water, drying the organic phase, filtering, concentrating, and recrystallizing to obtain the acetyl compound shown in the formula 2.
6. The method for preparing a phenol compound represented by formula 8 according to claim 5, wherein in the scheme a, the halogenated hydrocarbon solvent is one or more of chloroform, dichloromethane and dichloroethane;
And/or in the scheme a, the volume-mass ratio of the organic solvent to the trimethoprim is 8ml/g-10ml/g;
and/or, in the scheme a, the molar ratio of the acetylation reagent to the trimethoprim is 4:1-5:1;
and/or, in the scheme a, the molar ratio of the Lewis acid to the trimethoprim is 2:1-3:1;
and/or, in the scheme a, the temperature of the acetylation reaction is 60-65 ℃;
and/or in the scheme b, the halogenated hydrocarbon solvent is one or more of chloroform, dichloromethane and dichloroethane;
and/or in the scheme b, the volume-mass ratio of the organic solvent to the trimethoprim is 8ml/g-10ml/g;
and/or, in the scheme b, the molar ratio of the acetylation reagent to the trimethoprim is 4:1-5:1;
and/or, in the scheme b, the temperature of the acetylation reaction is 60 ℃ to 65 ℃.
7. The method for preparing a phenol compound according to claim 8, wherein when the method for preparing a phenol compound according to formula 8 further comprises the scheme b, the method for preparing a phenol compound according to formula 8 further comprises the scheme c, the scheme c comprising the steps of: performing acetylation reaction on trimethoprim shown in formula 1 under the action of an acetylating reagent in an organic solvent to obtain an acetamide compound shown in formula 1 a;
8. A method for preparing an acetyl compound shown in a formula 2, which is characterized by comprising a scheme a;
the scheme a comprises the following steps: in an organic solvent, in the presence of Lewis acid, carrying out an acetylation reaction shown below on trimethoprim and an acetylation reagent to obtain the acetyl compound shown in the formula 2;
in the scheme a, the Lewis acid is tin tetrachloride;
wherein the reaction conditions and operation in scheme a are as set forth in scheme a of any one of claims 4-7.
9. The preparation method of the acetophenone compound shown in the formula 3 comprises the following steps of carrying out the following acetamido hydrolysis reaction on the acetyl compound shown in the formula 2 in the presence of alkali in an organic solvent to obtain the acetophenone compound shown in the formula 3;
wherein the acetyl compound shown in the formula 2 is prepared by the scheme a according to any one of claims 4-7.
10. The method for producing an acetophenone compound represented by the formula 3 according to claim 9,
in the acetamido hydrolysis reaction, the organic solvent is an alcohol solvent;
And/or in the acetamido hydrolysis reaction, the volume-mass ratio of the organic solvent to the acetyl compound shown in the formula 2 is 5ml/g-15ml/g;
and/or, in the acetamido hydrolysis reaction, the base is an alkali metal carbonate;
and/or, in the acetamido hydrolysis reaction, the molar ratio of the base to the acetyl compound shown in the formula 2 is 0.1:1-1:1;
and/or, the temperature of the acetamido hydrolysis reaction is 60-82 ℃;
and/or, the preparation method further comprises post-treatment, wherein the post-treatment comprises the following steps: after the acetamido hydrolysis reaction is finished, the reaction system is subjected to crystallization, filtration, water washing and drying to obtain the acetophenone compound shown in the formula 3.
11. The method for producing an acetophenone compound of formula 3 according to claim 10, wherein the alcohol solvent is one or more of methanol, ethanol, and isopropanol in the acetamido hydrolysis reaction;
and/or in the acetamido hydrolysis reaction, the volume-mass ratio of the organic solvent to the acetyl compound shown in the formula 2 is 9ml/g-11ml/g;
And/or, in the acetamido hydrolysis reaction, the base is sodium carbonate and/or potassium carbonate;
and/or in the acetamido hydrolysis reaction, the molar ratio of the base to the acetyl compound shown in the formula 2 is 0.1:1-0.7:1;
and/or the temperature of the acetamido hydrolysis reaction is 65-70 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911126454.2A CN110724108B (en) | 2019-11-18 | 2019-11-18 | Esalapril Lin Zhongjian body and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911126454.2A CN110724108B (en) | 2019-11-18 | 2019-11-18 | Esalapril Lin Zhongjian body and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110724108A CN110724108A (en) | 2020-01-24 |
CN110724108B true CN110724108B (en) | 2023-04-28 |
Family
ID=69225305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911126454.2A Active CN110724108B (en) | 2019-11-18 | 2019-11-18 | Esalapril Lin Zhongjian body and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110724108B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894360A (en) * | 2021-09-30 | 2023-04-04 | 上海医药工业研究院 | Preparation method of chiral amine compound and intermediate thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115743A (en) * | 2005-02-18 | 2008-01-30 | 阿皮德公开股份有限公司 | Novel processes for the preparation of a 2H-chromene |
CN101611005A (en) * | 2006-12-22 | 2009-12-23 | 利奥制药有限公司 | Be used as the acetophenones of the replacement of PDE4 inhibitor |
CN102584773A (en) * | 2011-01-11 | 2012-07-18 | 昆明制药集团股份有限公司 | Method for preparing mangiferin aglycone |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014586A1 (en) * | 2003-08-08 | 2005-02-17 | Arpida Ag | Novel process for the preparation of 2h-chromenes |
-
2019
- 2019-11-18 CN CN201911126454.2A patent/CN110724108B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115743A (en) * | 2005-02-18 | 2008-01-30 | 阿皮德公开股份有限公司 | Novel processes for the preparation of a 2H-chromene |
CN101611005A (en) * | 2006-12-22 | 2009-12-23 | 利奥制药有限公司 | Be used as the acetophenones of the replacement of PDE4 inhibitor |
CN102584773A (en) * | 2011-01-11 | 2012-07-18 | 昆明制药集团股份有限公司 | Method for preparing mangiferin aglycone |
Non-Patent Citations (3)
Title |
---|
Fluorogenic Ubiquinone Analogue for Monitoring Chemical and Biological Redox Processes;Lana E. Greene等;《Journal of the American Chemical Society》;20160810;第138卷;第11329页方案2 * |
Heterocycles. Part XII. Synthesis of new benzo[6,7]cyclohepta[1,2-d]pyrimidine;N. R.El-Rayyes等;《Journal of Heterocyclic Chemistry》;19870831;第24卷(第4期);第1141-1147页 * |
Nobiletin metabolites: Synthesis and inhibitory activity against matrix metalloproteinase-9 production;Tetsuta Oshitari等;《Bioorganic & Medicinal Chemistry Letters》;20110612;第21卷;第4542页方案4 * |
Also Published As
Publication number | Publication date |
---|---|
CN110724108A (en) | 2020-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2397981C2 (en) | 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide synthesis method | |
JPH0249797A (en) | Production of erythromycin a oxime and salt thereof | |
CN108137589B (en) | Carboline derivatives as bromodomain inhibitors | |
CN110724108B (en) | Esalapril Lin Zhongjian body and preparation method thereof | |
WO2009039731A1 (en) | Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof | |
CN110746361B (en) | Esalapril Lin Zhongjian body and preparation method thereof | |
CN110724135B (en) | Esalapril Lin Zhongjian body and preparation method thereof | |
US9845315B2 (en) | Method for preparing Afatinib and intermediate thereof | |
CN110713483B (en) | Elaprepilin intermediate and preparation method of elaprilin | |
CN110818694B (en) | Esalapu Lin Zhongjian body and application thereof | |
CN110642792B (en) | Preparation method of ilaprine intermediate | |
CN108218928B (en) | Bicyclic derivatives of glucoside, preparation method and application thereof | |
CN110790753B (en) | Ealaprilin p-toluenesulfonate, and preparation method and application thereof | |
US10815216B2 (en) | Process for the preparation of aripiprazole lauroxil | |
WO2005019223A1 (en) | Method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1- piperidino]- carbonyloxycamptothecin | |
WO2022127327A1 (en) | Bosutinib 1,3-propanediether dimer impurity and preparation method therefor | |
CN110563670B (en) | Sulfur-containing piperazine derivative and application thereof | |
JP2641542B2 (en) | Method for producing asymmetric dihydropyridines | |
WO2009049493A1 (en) | Preparation of seselin and its derivatives | |
JPH05339271A (en) | Quinoline derivative or its salt | |
CN114507220B (en) | Substituted 4-phenyl-5-functionalized 1,2, 4-triazole derivative and preparation method and application thereof | |
CN115181112B (en) | Synthesis and anti-tumor application of 6-bromo-cycloicaritin chromane 3, 4-diketone derivative | |
CN112321486B (en) | Synthesis method of 4-hydroxy-3, 3-dimethyl-2H-benzo [ g ] indole-2, 5 (3H) -dione | |
CN110818676A (en) | Crystal form of cyclohexane derivative | |
KR100502834B1 (en) | The preparation method of simvastatin by improved process of lactonization and its purification process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 200040 No. 1320 West Beijing Road, Shanghai, Jingan District Applicant after: Shanghai Pharmaceutical Industry Research Institute Co.,Ltd. Applicant after: China Pharmaceutical Industry Research Institute Co.,Ltd. Address before: 200040 No. 1320 West Beijing Road, Shanghai, Jingan District Applicant before: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Applicant before: CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY |
|
GR01 | Patent grant | ||
GR01 | Patent grant |